RPIA

Across TCGA pan-cancer cohorts, RPIA mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RPIA data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RPIA mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RPIA expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and OV are the cancer types where RPIA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.659	0.411	<.001	92	view →
CCRCC	DFS	Median	All	0.913	0.584	<.001	27	view →
OV	DFS	Tertile	All	0.922	0.535	.045	8	view →
LUAD	DFS	Quartile	III,IV	0.264	0.944	.006	7	view →
GBM	OS	Median	All	0.591	0.464	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RPIA–PDAC (OS)

Open the PDAC breakdown →